A trial that assessed the effect of a direct renin inhibitor (aliskiren) combined with either an ACE inhibitor or an angiotensin-receptor-blocker–ARB in type 2 diabetics with increased risk of cardiovascular and renal events

Conclusion All primary outcomes–cardiovascular death, myocardial infarction, stroke, end-stage kidney disease, and kidney-related death were more common in the combination therapy arms, which led to the trial’s early termination. 

Abbreviation for Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints

Reference Cleveland Clinic J of Med 2013; 80:209-217

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.